NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

LatInamerican Vaccine Effectiveness Against Hospitalizations Due to Circulating COVID-19 VoC RWE Study
LatInamerican Vaccine Effectiveness Against Hospitalizations Due to Circulating COVID-19 VoC RWE Study

NCT05282017

CompletedN/A

Sponsor: AstraZeneca

Conditions: COVID-19, SARS-CoV-2

Countries: Brazil, Colombia, Costa Rica, Mexico, Panama

COVID-19 is the infectious disease caused by the novel coronavirus known as SARS-CoV-2, that appeared in 2019. The World Health Organisation (WHO) declared the novel coronavirus a pandemic on 11 March 2020. The evolution of the pandemic is varying across countries, affected in part by different containment strategies ranging from extreme lockdown to relative inaction. As a result, there are regional waves of the disease and pockets of vulnerable populations. Globally, governments have acknowledged that effective vaccines against COVID-19 are the only way to guarantee a safe and sustained exit strategy from repeated lockdowns. The objective of this study is to estimate the vaccine effectiveness against hospitalizations due to circulating COVID-19 VoC among subjects eligible for vaccination with the AstraZeneca or any other COVID-19 vaccine provided in their country as per national/regional immunization recommendations prior to hospital admission. The study design is an observational prospective active-surveillance hospital-based study, with a test-negative case-control design (TNCC) of hospitalized COVID-19 like cases undergoing testing for SARS-CoV-2

Eligibility overview

Sex: ALL

Age: 18 Years to 100 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* 18y and older
* Ever eligible for vaccination with the AstraZeneca or any other COVID-19 vaccine provided in their country as per national/regional immunization recommendations prior to hospital admission.
* Hospitalization due to COVID-19 like case
* Willing and able to provide informed consent (or by legal accepted representative if patient are not able to provide their signature by themselves)

Exclusion Criteria:

* Cannot be swabbed or other conditions that contra-indicate swabbing
* COVID-19 hospitalization within 3 months prior to the current admission. Hospital transfers are not considered as a prior hospitalization.
Locations (9)
  • Brazil, Rio de Janeiro, Brazil
  • Brazil, Salvador, Brazil
  • Brazil, São Paulo, Brazil
  • Bogotá, Colombia
  • Cali, Colombia
  • San José, Costa Rica
  • Guadalajara, Jalisco, Mexico
  • Mérida, Yucatán, Mexico
  • Panama City, Panama